GlassScriptPhysician profile
Parth Vijay Khade
NPI 1942620216
$28,083.94
in general payments reported to CMS, 2019-2025
47 companies · $9,110 in 2025
The $9,110 reported for 2025 was more than what 80% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,004 · 2020: $233 · 2021: $923 · 2022: $9,866 · 2023: $2,529 · 2024: $4,419 · 2025: $9,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,600 · Travel and Lodging: $4,210 · Food and Beverage: $2,385 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Honoraria: $1,700 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,600.00 |
| Travel and Lodging | $4,209.65 |
| Food and Beverage | $2,385.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Honoraria | $1,700.00 |
| Education | $162.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $5,362.21 | 2022 | |
| Avyxa Pharma, LLC | $3,511.31 | 2025 | |
| Pharmacosmos Therapeutics INC. | $3,285.97 | 2024 | Monoferric |
| E.R. Squibb & Sons, L.L.C. | $2,835.98 | 2022-2025 | Opdivo |
| Springworks Therapeutics, INC. | $1,800.00 | 2025 | Ogsiveo |
| Epizyme, INC. | $1,710.28 | 2022-2023 | Tazverik |
| Rigel Pharmaceuticals, INC. | $1,535.71 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $1,372.68 | 2019-2025 | Imfinzi, Calquence |
| Glaxosmithkline, LLC. | $1,216.48 | 2021-2025 | Jemperli |
| Seagen INC. | $684.71 | 2019-2023 | Tukysa |
| Novartis Pharmaceuticals Corporation | $561.40 | 2022-2025 | |
| Incyte Corporation | $447.20 | 2022-2025 | Jakafi |
| Merck Sharp & Dohme LLC | $415.62 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Janssen Scientific Affairs, LLC | $319.94 | 2022 | |
| Lilly USA, LLC | $300.20 | 2019-2024 | Verzenio, Jaypirca |
Show all 44 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parth Khade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.